Leaderboard
Anzeige
medline.ch
En
|
De
Impressum
No articles selected!
View Cart
You are here:
Oncology
»
Urologic Neoplasms
21. November 2026
Search
medline.ch
Urologic Neoplasms
Advanced search
Dermatology
Endocrinology
Nutrition
Gastroenterology
Gynecology
Haematology
Infectious diseases
Cardiovascular Diseases
Musculoskeletal Diseases
Neurology
Oncology
Musculoskeletal System
Blood
Endocrine System
Gynecologic Neoplasms
Skin
Gastrointestinal
ORL
Respiratory Tract
Urologic Neoplasms
CNS
ORL
Pediatrics
Psychiatry
Respiratory Tract
Sports
Urology-Nephrology
Rect Top
Anzeige
Zoom:
Page 1 of 9157
Articles 1 - 20 / 183136
Multimodal lifestyle strategies for ADT-induced osteosarcopenia and metabolic dysfunction in prostate cancer.
Support Care Cancer
Ambrosio F, Persia M, Bellieni A, Tagliaferri L, Gambacorta MA, Frascino V, Abbatecola G, Landi F, Colloca GF.
PMID: 43064850 [PubMed - indexed for MEDLINE]
Small size, major effect: microRNAs shaping testicular germ cell tumour biology and clinical practice.
Nat Rev Urol
Tavares NT, Oliveira-Lopes B, Weiss RS, Bagrodia A, Hamilton RJ, Heidenreich A, Henrique R, Jerónimo C, Lobo J.
PMID: 43064732 [PubMed - as supplied by publisher]
Artificial Intelligence in Screening and Early Detection of Prostate Cancer.
Eur Urol Focus
Cacciamani GE, Pannu AS, Thimansson E, Bjartell A.
PMID: 43064602 [PubMed - as supplied by publisher]
Prognostic utility of preoperative NLR, PLR, SII in penile cancer: A National Cohort Study.
Urol Oncol
Sugrue DD, Eddershaw C, Ryan F, Kuar I, Chaoimh DN, Chinneide EN, Teo MY, Davis NF, Cullen IM.
PMID: 43064572 [PubMed - as supplied by publisher]
Re: Stereotactic Body Radiotherapy Versus Moderately Hypofractionated IMRT for Localized Intermediate-risk Prostate Cancer: A Randomized Clinical Trial.
Eur Urol
Kishan AU, Samala SK, Nagar H.
PMID: 43064549 [PubMed - as supplied by publisher]
Re: Anke Richters, Marinde J. G. Bond, Hans M. Westgeest, et al. Development and External Validation of a New Prognostic Model for Metastatic Clear Cell Renal Cell Carcinoma: A Preregistered Analysis Using Data from Randomised Clinical Trials in the Checkpoint Inhibitor Era. Lancet Oncol 2026;27:1295-303.
Eur Urol
Massari F, Rosellini M, Santoni M, Mollica V.
PMID: 43064548 [PubMed - as supplied by publisher]
Prostate and pelvic nodal stereotactic body radiotherapy (SBRT) versus prostate-only SBRT for high-risk, localised prostate cancer (PACE-NODES): early adverse event results from an international, open-label, phase 3, randomised controlled trial.
Lancet Oncol
Pathmanathan A, Jain S, Cafferty FH, Leaning D, Chan A, Venkitaraman R, Varughese M, Panades M, Ward T, Tree A, Syndikus I, Staffurth J, Song YP, Das P, McGrane J, Pugh J, Naismith O, Murthy V, McGarry CK, McBride K, Kelly P, Hoskin P, Hallett J, Dewan M, Clees-Baron H, Choudhury A, Burnett S, Brown S, Hall E, van As N.
PMID: 43063962 [PubMed - as supplied by publisher]
Metformin use and all-cause and cause-specific mortality in patients with kidney cancer: a nationwide Korean cohort study.
Cancer Treat Res Commun
Sim Y, Jung G, Shim M, Kim JH, Kim MJ, Kim Y, Kim YJ, Kim KN, Jo JK.
PMID: 43063679 [PubMed - as supplied by publisher]
Overall Survival With [(177)Lu]Lu-PSMA-617 in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Bayesian Reanalysis of the PSMAfore Trial.
JCO Clin Cancer Inform
Satapathy S, Chandekar KR.
PMID: 43063372 [PubMed - indexed for MEDLINE]
Evaluation of the efficacy and safety of particle therapy for kidney cancer through a multicenter registry study and meta-analysis.
J Radiat Res
Nishioka K, Ishikawa H, Maruo K, Kawamura H, Iizumi T, Sato H, Toyama S, Mori T, Suzuki O, Okimoto T, Ogino T, Murakami M, Tamamura H, Shibamoto Y, Umehara K, Hashimoto T, Aoyama H, Sakurai H.
PMID: 43062948 [PubMed - as supplied by publisher]
Comparative effectiveness and treatment modification of first-line apalutamide versus enzalutamide in metastatic castration-sensitive prostate cancer: a propensity score-matched multicenter study.
Jpn J Clin Oncol
Ohtani M, Narita T, Miyauchi K, Morishita S, Fujita N, Kikuchi D, Abe N, Kobayashi S, Wada N, Hatakeyama S, Numakura K.
PMID: 43062936 [PubMed - as supplied by publisher]
Concurrent bone-modifying agent use and fracture risk in patients treated with radium-223 for metastatic castration-resistant prostate cancer: A Japanese claims database study.
Ann Nucl Med
Takeda K, Umezawa R, Yamamoto T, Takahashi N, Jingu K.
PMID: 43062625 [PubMed - as supplied by publisher]
Prediction models for progression to castration-resistant prostate cancer after androgen deprivation therapy: a narrative review (2021-2026).
Front Oncol
Yuan J, Jiang Z, Chen W, Wang S.
PMID: 43061358 [PubMed]
Comparative Analysis of CNN Architectures for High-Accuracy Subtype Classification of Renal Cell Carcinoma Using CECT.
IEEE Open J Eng Med Biol
M G RK, Laju PK, Bhat V, T A, K P, H A.
PMID: 43061253 [PubMed]
Bayesian deep learning framework to address multi-rater annotation uncertainty in prostate cancer magnetic resonance imaging segmentation.
Phys Imaging Radiat Oncol
Liang X, Kabir T, Tammisetti VS, Giancardo L, Shams S.
PMID: 43061230 [PubMed]
Focal Versus Whole-Gland Cryoablation Therapy in High-Grade Prostate Cancer: A Single-Institution Retrospective Study.
Cureus
Khan A, Shawwa J, Ho A, Coletta D, Dalal A, Feloney M, Khan AU.
PMID: 43061079 [PubMed]
Association Between Prostate Volume and PI-RADS v2.1 Performance for Detecting Clinically Significant Prostate Cancer in Men in the PSA Gray Zone: A Retrospective Study.
Cancer Manag Res
Li Q, Zhao Y, Tang L, Zheng J, Li L.
PMID: 43060703 [PubMed]
Statement of Retraction: Increased expression of tribbles homolog 3 predicts poor prognosis and correlates with tumor immunity in clear cell renal cell carcinoma: a bioinformatics study.
Bioengineered
PMID: 43059549 [PubMed - in process]
Glutamine metabolic reprogramming remodels the immunosuppressive microenvironment and modulates immunotherapy response in renal cell carcinoma (Review).
Oncol Rep
Liu Y, Liu W, Zhang L, Wang Y, Chai K, Ye Y.
PMID: 43059384 [PubMed - indexed for MEDLINE]
Impact of pioglitazone use on clinicopathological features and aggressiveness of bladder cancer: a retrospective cohort study.
BMC Urol
Cin H, Gülmez H, Turan T.
PMID: 43058660 [PubMed - in process]
Articles 1 - 20 / 183136
Page 1 of 9157
Rect Bottom
Anzeige
Adserver Footer
Time frame
--unlimited--
1 Week
1 Month
3 Months
6 Months
1 Year
2 Years
3 Years
5 Years
10 Years
Sky right 1
Anzeige
Mediscope AG E-mail:
info@mediscope.ch
Disclaimer
|
Privacy Policy